4/8/2014

Bristol-Myers Squibb has filed new-drug applications with the FDA for approval to market its experimental drugs daclatasvir and asunaprevir as a treatment for hepatitis C genotype 1b. The combination regimen previously received breakthrough therapy status from the FDA.

Full Story:
FDAnews

Related Summaries